COVID-19: KEEPING UP WITH A MOVING TARGET July 1, 2020 UPDATE

Paul Auwaerter, MD, MBA, FIDSA Clinical Director, Division of Infectious Diseases Sherrilyn and Ken Fisher Professor of Medicine Fisher Center for Environmental Infectious Diseases Johns Hopkins University School of Medicine Baltimore, Maryland









Jointly provided by Postgraduate Institute for Medicine, DKBmed, and the Institute for Johns Hopkins Nursing.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Name of Faculty or Presenter	Reported Financial Relationship
Paul G. Auwaerter, MD, MBA, FIDSA	Scientific Advisor: DiaSorin, Shionogi Inc. JNJ: Ownership equity

Dr. Auwaerter has indicated that he will be referencing the unlabeled or unapproved use of agents currently being investigated in on-going studies and trials. These include hydroxychloroquine/chloroquine, hydroxychloroquine/chloroquine in combination with azithromycin, lopinavir plus ritonavir, tocilizumab, corticosteroids, and COVID-19 convalescent plasma.

All activity, content, and materials have been developed solely by the activity directors, planning committee members, and faculty presenters, and are free of influence from a commercial entity.







CME Information

To attest for CME/CE/AAPA credit, please visit COVID19.dkbmed.com





Learning Objectives

- Discuss the current trend in three-day rolling averages of new cases
- Describe the results of the CDC's seroprevalence study
- Discuss the implications of the conclusions of the seroprevalence data (eg, public health messages)







This activity is supported by an educational grant from Pfizer, Inc. and in-kind support by DKBmed, LLC.

All activity content and materials have been developed solely by the activity directors, planning committee members, and faculty presenters, and are free of influence from Pfizer, Inc.

Please see **COVID19.DKBmed.com** for additional resources and educational activities





Paul Auwaerter, MD, MBA, FIDSA

Clinical Director, Division of Infectious Diseases Sherrilyn and Ken Fisher Professor of Medicine Fisher Center for Environmental Infectious Diseases Johns Hopkins University School of Medicine Baltimore, Maryland





Total Global Cases (7/1/20)



coronavirus.jhu.edu/map.html





Summertime and the Livin Isn't Easy

- The clinician as a travel advisor
 - Should I stay or should I go?
- Do I invite/go see family or friends?

Q: I'm from NYC, should I visit my family in South Carolina this weekend?

Q: I was at a garden party 3 days ago with 25 people, 1 now ill and COVID-19 positive. What should I do?

Q: My 18 y.o. son hangs out with a friend whose mother is COVID-19 (+), but the boy has tested (-). Can he stay at our house?





Three-Day Rolling Average

New confirmed cases per 1,000 people



- States with initially low frequencies leading—except CA

 Relaxation to open the economy
 Mixed messaging
 - Mask wear
 - Social distancing
 - > Younger people
 - \circ Some rollback
 - Will initial wave states hold low rates?





Numbers to Watch: Statewide COVID-19 (+)%

This page was last updated on Wednesday, July 1, 2020 at 03:00 AM EDT.



https://coronavirus.jhu.edu/testing/testing-positivity (July 1, 2020)







NYC Data – Daily Testing Comparison



https://www1.nyc.gov/site/doh/covid/covid-19-data.page







COVID-19 Antibody Seroprevalence

CDC survey—six regions, using (S) protein specific antibody for SARS-CoV-2, adjusted results based on 96.0% sensitivity and 99.3% specificity of their assay

[used screening and then second confirmatory assay]

Sites: CT, southern FL, MO, NYC metro area, UT and WA Puget Sound region N = 11,933 persons Sera as convenience samples (collected at Quest or LabCorp for other purposes)





HOME ABO



O Comment on this paper

Seroprevalence of Antibodies to SARS-CoV-2 in Six Sites in the United States, March 23-May 3, 2020

Fiona P. Havers, Carrie Reed, Travis W. Lim, Joel M. Montgomery, John D. Klena, Aron J. Hall, Alicia M. Fry, Deborah L. Cannon, Cheng-Feng Chiang, Aridth Gibbons, Inna Krapiunaya, Maria Morales-Betoulle, Katherine Roguski, Mohammed Rasheed, Brandi Freeman, Sandra Lester, Lisa Mills, Darin S. Carroll, S. Michelle Owen, Jeffrey A. Johnson, Vera A. Semenova, State Collaborator Group, Jarad Schiffer, Datalie P.Thornburg





Percentages by Geography

Figure 1.



DATE SAMPLES COLLECTED







Percentages by Demographics (with Time of Collections)

Figure 2.



https://www.medrxiv.org/content/10.1101/2020.06.25.20140384v1 (6/26/20)





COVID-19 Antibody Seroprevalence

Highlights:

- Infection rates 6-23x, compared to confirmed COVID-19, depending on location
- 10x in most active regions: NYC metro area and WA Puget Sound locations

Conclusions:

- High rates of mild or asymptomatic infection
- Needs confirmation (some false positives especially in lower prevalence states, multiple samples from same person?)

medRχiv (CSH) THE PREPRINT SERVER FOR HEALTH SCIENCES

HOME | ABO

Search

O Comment on this paper

Seroprevalence of Antibodies to SARS-CoV-2 in Six Sites in the United States, March 23-May 3, 2020

Fiona P. Havers, Carrie Reed, Travis W. Lim, Joel M. Montgomery, John D. Klena, Aron J. Hall, Alicia M. Fry, Deborah L. Cannon, Cheng-Feng Chiang, Aridth Gibbons, Inna Krapiunaya, Maria Morales-Betoulle, Katherine Roguski, Mohammed Rasheed, Brandi Freeman, Sandra Lester, Lisa Mills, Darin S. Carroll, S. Michelle Owen, Jeffrey A. Johnson, Vera A. Semenova, State Collaborator Group, Jarad Schiffer, Datalie P. Thornburg

BMI

Yale





COVID-19 Antibody Seroprevalence

Study reinforces public health messages

- 1. Wear a mask in public
- 2. Maintain social distancing
- 3. Hand hygiene
- 4. Self-isolate if sick or recent close contact

medRxiv Cold Spring Harbor Laboratory BMJ Yale

HOME | ABO

Search

O Comment on this paper

Seroprevalence of Antibodies to SARS-CoV-2 in Six Sites in the United States, March 23-May 3, 2020

Fiona P. Havers, Carrie Reed, Travis W. Lim, Joel M. Montgomery, John D. Klena, Aron J. Hall, Alicia M. Fry, Deborah L. Cannon, Cheng-Feng Chiang, Aridth Gibbons, Inna Krapiunaya, Maria Morales-Betoulle, Katherine Roguski, Mohammed Rasheed, Brandi Freeman, Sandra Lester, Lisa Mills, Darin S. Carroll, S. Michelle Owen, Jeffrey A. Johnson, Vera A. Semenova, State Collaborator Group, Jarad Schiffer, Datalie P.Thornburg

https://www.medrxiv.org/content/10.1101/2020.06.25.20140384v1 (6/26/20)





Milton Glaser, dead at age 91, graphic designer "I♥NY"



At the time of his death, Milton Glaser was working on a graphical treatment of the word "Together," to evoke the idea that during the separation of the pandemic, "we have something in common." Milton Glaser









To submit your own question, please email QA@dkbmed.com







How soon after exposure will an individual typically test positive for COVID-19?







What are your thoughts and opinions about the JAMA Greek colchicine study for COVID-19 patients?







I recently read an article that showed some promise using low dose radiation to combat the cytokine storm. What are your thoughts about this approach?







To receive CME/CE/AAPA credit:

- Complete the evaluation on at COVID19.DKBmed.com
- Upon registering and successfully completing the activity evaluation, you will have immediate access to your certificate.

To access more resources related to COVID-19:

• Access our resource hub at COVID19.DKBmed.com

To ask your own question, email:

• QA@dkbmed.com

